NAS10028,437+0.91%S&P7,689+1.58%GOLD$4,142+1.70%BTC$80,182−0.28%VIX16.80+1.14%latest tape · as of 12:01 UTC
The Screen · Basic Materials · Building Materials
CRH plc
CRH · a US exchange · USD · Market cap $60.3B · 83,032 employees
CRH plc, together with its subsidiaries, provides building materials solutions in Ireland, the United States, the United Kingdom, rest of Europe, and internationally.
FAIL · Does not pass the screen
98.80 USD
Price as of 4 Nov 2026Daily close, not a live quote
Screened 2026-11-04 · the tape above runs as of 12:01 UTC · two dates, stated on purpose · verdict and workings shown in full · never trimmed
Key facts today
Price98.80 USD at the 4 Nov 2026 close
Our value readFair vs our fair value, as of 4 Nov 2026
Positioning no disclosures inside 60 days, left as found
Options put/call open interest 0.78, read 2026-11-01
Ethical does not pass the values gate
Price98.80 USD
Fair value86.32
Ethical score10.0/100
Value readFairas of 4 Nov 2026
Our investment reviews on this name
2026-11-05Read Markup98.80+0.0% to today ✓Accumulation gives way to Markup after a 20% rise in 10 days
2026-10-26Read Accumulation82.32+20.0% to today ✓Markdown gives way to Accumulation with deal news in the headlines
2026-10-02Read Markdown85.04+16.2% to today Distribution gives way to Markdown after a 19% slide in 13 weeks
2026-07-02Read Distribution105.06-6.0% to today ✓First review on file: Distribution
Our analytic regime reads on this name, dated and marked against the screened price. Small sample per name, and separate from the daily-framework accuracy on the Track Record page.
CRH plc holds its Markup at $98.80. The statistical read favours the buyers, held for 4 days.
As held on the ledger · 2026-11-04
Phase
Markup
Quantitative state
The statistical read favours the buyers, held for 4 days
Price at the screen
$98.80
Valuation
16.01 trailing · 14.28 forward price to earnings
Values screen
FAIL· score 10.0
Beta
1.19
The Workings
Five Screens, Shown in Full
Does not pass. Debt ratio
Test
Figure
Limit
What it means
Status
Business activity
Permissible
Core business clean
Its core business isn't built on prohibited lines: no gambling, alcohol, tobacco, weapons, or interest-based lending.
Pass
Debt load
33.78%
Below 33%
Interest-bearing debt is 33.8% of its assets, above the one-third ceiling the screen allows.
Fail
Interest-bearing cash
0.00%
Below 33%
Cash held in interest-bearing accounts and securities is 0.0% of assets, under the one-third limit.
Pass
Receivables
14.39%
Below 49%
Money owed to the company is 14.4% of assets, under the 49% limit.
Pass
Revenue purity
0.39%
Below 5%
Only 0.4% of revenue comes from non-compliant sources, under the 5% line.
Pass
Five checks adapted from AAOIFI screening standards: business activity plus four balance-sheet ratios. All five must pass for ethical clearance. Every figure is arithmetic on public accounts, not judgement.
The Ethical Read
Why It Falls Short, in Plain English
CRH's business is in a permissible area, but its interest-bearing debt is about 34% of the company, just over the ~33% line, so it does not pass on the financial screens.
Read as at 2026-11-05. It updates when the underlying figures move, and past reads are kept below.
Follow this verdict
Get an email when CRH's ethical verdict changes
Today CRH does not pass the screen. If new figures move it to a pass, we send you one short email with the before and after. Verdicts change rarely, so you may not hear from us for a long time.
Free, no account needed. Every email has a link to stop.
What the Numbers Say It Is Worth
The Fair Value Range
Our analysis reads Fair vs our fair value, as of 4 Nov 2026: it trades above our $86.32 fair value estimate, narrow competitive moat, 5.60% revenue growth.
Fair value range in USD, drawn from the 2026-11-04 screen. The gold marker is the market price at the same screen. The price runs 14.5% above the base estimate.
Third-party analyst targets: 24 covering, consensus Strong Buy. The average target sits +20% from the screen price.
Reading the gap · Our more conservative model reads it as fully-to-richly valued here, while the Street is more bullish: a quality-at-a-fair-price name rather than a deep-value one.
Where our models see it going: fair-value estimate $86.32, with a range of $86.32 to $99.27, dated to the 2026-11-04 screen.
Fair value and rating are our own model estimates; the Street's range reflects third-party analyst estimates. Analysis, not advice.
The Business, in Plain Words
Construction booms hide the cycle trap
Roads, offices and homes all need aggregates and cement, yet the building cycle rarely stays kind for long. CRH trades above our fair value with a negative margin of safety and a forward multiple that flatters peak earnings in a notoriously cyclical sector. We pass.
Revenue growth sits at nine percent and return on equity reaches sixteen percent, yet the narrow moat and ten percent profit margin leave little room for error once volumes turn. The ethical screen also flags excessive debt, ruling the name out regardless of analyst enthusiasm.
High debt and exposure to construction swings create real downside when rates stay elevated or spending slows. The apparent value is a warning, not an opportunity. Analysis, not advice.
Another profit measure, before interest, tax and non-cash costs: EBITDA.
The risks · The things to watch: its business and earnings are exposed to Ireland and to currency swings.
Plain-English interpretation of our own screen data. Analysis, not advice.
Where & How to Trade
CRH trades on a US exchange (the company is based in Ireland). As a listed security it is accessible through almost any international broker offering its home market. New to this, or investing from abroad? Our guide to accessing global markets covers brokers, currencies and the practical steps.
The Dated Journal · Newest First, Never Edited
Every Entry, As Written
2026-11-05Markup · changed$98.80+16.4%Entry 22
The framework has shifted from accumulation to markup since the last review. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved up 16.4% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading neutral. Over the past year the shares are up 9%. Our forward projection puts the odds of a 10% gain over the next month near 23%. The street (24 analysts) rates it strong buy, with a mean price target of $143. Since the last review it its composite score eased.
2026-10-29Accumulation$84.89+3.1%Entry 21
The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved up 3.1% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading neutral. Over the past year the shares are up 9%. Our forward projection puts the odds of a 10% gain over the next month near 23%. The street (24 analysts) rates it strong buy, with a mean price target of $143. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-28Accumulation$82.32+0.0%Entry 20
The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading neutral. Over the past year the shares are up 9%. Our forward projection puts the odds of a 10% gain over the next month near 23%. The street (24 analysts) rates it strong buy, with a mean price target of $143. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-27Accumulation$82.32+0.0%Entry 19
The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading neutral. Over the past year the shares are up 9%. Our forward projection puts the odds of a 10% gain over the next month near 23%. The street (24 analysts) rates it strong buy, with a mean price target of $143. It reported earnings in this window, a natural checkpoint for the thesis.
The framework has shifted from markdown to accumulation since the last review. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading neutral. Over the past year the shares are up 9%. Our forward projection puts the odds of a 10% gain over the next month near 23%. The street (24 analysts) rates it strong buy, with a mean price target of $143. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-25Markdown$82.32+0.0%Entry 17
The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it D, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading neutral. Over the past year the shares are up 9%. Our forward projection puts the odds of a 10% gain over the next month near 23%. The street (24 analysts) rates it strong buy, with a mean price target of $143. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-24Markdown$82.32+0.0%Entry 16
The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it D, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading neutral. Over the past year the shares are up 9%. Our forward projection puts the odds of a 10% gain over the next month near 23%. The street (24 analysts) rates it strong buy, with a mean price target of $143. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-23Markdown$82.32+0.0%Entry 15
The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it D, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading neutral. Over the past year the shares are up 9%. Our forward projection puts the odds of a 10% gain over the next month near 23%. The street (24 analysts) rates it strong buy, with a mean price target of $143. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-22Markdown$82.32+1.0%Entry 14
The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved up 1.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it D, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading neutral. Over the past year the shares are up 9%. Our forward projection puts the odds of a 10% gain over the next month near 23%. The street (24 analysts) rates it strong buy, with a mean price target of $143. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-15Markdown$81.54-4.1%Entry 13
The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 4.1% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it D, carrying a low risk profile. Technically it is momentum reading bearish. Over the past year the shares are up 9%. Our forward projection puts the odds of a 10% gain over the next month near 23%. The street (24 analysts) rates it strong buy, with a mean price target of $143.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.
